Patents Assigned to Pharma Mar, S.A.
-
Publication number: 20070190164Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/M2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.Type: ApplicationFiled: November 15, 2004Publication date: August 16, 2007Applicant: PHARMA MAR, S.A.U.Inventor: Mary Rybak
-
Patent number: 7247629Abstract: Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.Type: GrantFiled: May 15, 2001Date of Patent: July 24, 2007Assignee: Pharma Mar, S.A.Inventors: Ignacio Manzanares, María Jesús Martin, Alberto Rodriguez, Simon Munt, Carmen Cuevas, Marta Perez
-
Patent number: 7241892Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically: R1 is an amidomethylene group or an acyloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.Type: GrantFiled: May 15, 2000Date of Patent: July 10, 2007Assignee: Pharma Mar, S.A.Inventors: Carmen Cuevas, Marta Perez, Andres Francesch, Carolina Fernandez, Jose Luis Chicharro, Pilar Gallego, Maria Zarzuelo, Fernando de la Calle, Ignacio Manzanares
-
Publication number: 20070128201Abstract: ET-743 can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.Type: ApplicationFiled: June 1, 2004Publication date: June 7, 2007Applicant: Pharma Mar, S.A.U.Inventors: Maurizio D'Incalci, Luca Gianni, Raffaella Giavazzi, Margarita Martin, Ian Judson, Jose Donaque, Cristiana Sessa
-
Publication number: 20070093658Abstract: Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided.Type: ApplicationFiled: February 4, 2003Publication date: April 26, 2007Applicant: Pharma Mar, S.A.Inventor: Valentin Martinez
-
Publication number: 20070082856Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of doxorubicin is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with doxorubicin in a dose range between 40 and 80 mg/m2.Type: ApplicationFiled: November 12, 2004Publication date: April 12, 2007Applicant: Pharma Mar, S.A.U.Inventors: Luca Gianni, Maurizio D'Incalci, Filippo de Braud, Silvia Marsoni, Jose Donaque, Luis Lazaro
-
Patent number: 7138547Abstract: New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, CN, halogen, C(?O)H, C(?O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1–C18 alkyl, substituted or unsubstituted C2–C18 alkenyl, substituted or unsubstituted C2–C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form ?O; Y is NR1, OR1, PR1, SR1, or halogen, wherein the number of substituents R1 is selected to suit the valency and each R1 is independently selected of H, OH, C(?O)R?, P(?O)R?R?, substituted or unsubstituted C1–C18 alkyl, substituted or unsubstituted C2–C18 alkenyl, substituted or unsubstituted C2–C18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHC(O)R?, CN, halogen, C(?OType: GrantFiled: June 6, 2001Date of Patent: November 21, 2006Assignee: Pharma Mar, S.A.Inventors: Jose Luis Aceña, Javier Adrio, Carmen Cuevas, Pilar Gallego, Ignacio Manzanares, Simon Munt, Ignacio Rodriguez
-
Patent number: 7135494Abstract: The invention provides a compound of formula (I). This invention relates to heterocyclic compounds. It further relates to methods for their preparation, compositions cotaining them and their use as a medicament, particularly as a medicament for the treatment and prophylaxis of cancer.Type: GrantFiled: December 13, 2001Date of Patent: November 14, 2006Assignee: Pharma Mar, S.A.Inventors: Murray Herbert Gibson Munro, Sylvia Urban, John Wilson Blunt, Dolores Garcia Gravalos
-
Patent number: 7115743Abstract: The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as “ETM” followed by a numeric value which represents the approximate molecular weight. Three compounds have been identified to date, namely ETM 305, ETM 775 and ETM 204.Type: GrantFiled: December 10, 2004Date of Patent: October 3, 2006Assignee: Pharma Mar, S.A.Inventors: Kenneth L. Rinehart, Jose J. Morales, Joel Reid, Isabel Reymundo, Pablo Floriano, Lola Garcia Gravalos
-
Publication number: 20060019960Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.Type: ApplicationFiled: January 26, 2005Publication date: January 26, 2006Applicant: Pharma Mar, S.A.Inventors: Ignacio Manzanares, Maria Martin, Alberto Rodriguez, Simon Munt, Carmen Cuevas, Marta Perez
-
Patent number: 6867334Abstract: The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as “ETM” followed by a numeric value which represents the approximate molecular weight. Three compounds have been identified to date, namely ETM 305, ETM 775 and ETM 204.Type: GrantFiled: October 3, 2001Date of Patent: March 15, 2005Assignee: Pharma Mar, S.A.Inventors: Kenneth L. Rinehart, Jose J. Morales, Joel Reid, Isabel Reymundo, Pablo Floriano, Lola Garcia Gravalos
-
Patent number: 6864283Abstract: Compounds of formula (I) wherein R1is selected from H, C(?O)R?, P(?O)R?R?, S(?O)R?R?, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, or substituted or unsubstituted aryl; or R1 together with R2 forms a saturated or unsaturated heterocyclic ring; R2 and R3 are each, independently, selected from H, C(?O)R?, P(?O)R?R?, S(?O)R?R?, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, or substituted or unsubstituted aryl; or one of R2 or R3 together with R1 forms a saturated or unsaturated heterocyclic ring; or R2 and R3 together form a saturated or unsaturated heterocyclic ring; R4 is selected from H, C(?O)R?, P(?O)R?R?, S(?O)R?R?, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18, alkynyl, or substituted or unsubstituted aryl, wherein R? is selected from the group consisting ofType: GrantFiled: February 16, 2001Date of Patent: March 8, 2005Assignee: Pharma Mar, S.A.Inventors: Tatsuo Higa, Junichi Tanaka, Dolores Garcia Gravalos
-
Patent number: 6710029Abstract: Dehydrodidemnin B with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivatives.Type: GrantFiled: July 19, 2000Date of Patent: March 23, 2004Assignee: Pharma Mar S.A.Inventors: Kenneth L. Rinehart, Anna M. Lithgow-Bertelloni
-
Publication number: 20040033940Abstract: Disclosed is a new cyclic heptapeptide, trunkamide A, with antitumor activity. The compound trunkamide A has been isolated from a Lissoclinum sp. collected on the Great Barrier Reef, Australia.Type: ApplicationFiled: August 16, 2002Publication date: February 19, 2004Applicant: Pharma Mar, S.A.Inventors: Bruce Frederick Bowden, Dolores Garcia Gravalos
-
Patent number: 6635656Abstract: Compounds of general formula (I), wherein the nature of the group R is not particularly critical and typically takes various forms, include the natural compound halitulin of formula (I) and have antitumor activity.Type: GrantFiled: November 7, 2001Date of Patent: October 21, 2003Assignee: Pharma Mar, S.A.Inventors: Yoel Kashman, Ganit Koren-Goldshlager, Maria Dolores Garcia Gravalos, Michael Schleyer
-
Publication number: 20030148933Abstract: Dehydrodidemnin with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivatives.Type: ApplicationFiled: February 4, 2003Publication date: August 7, 2003Applicant: Pharma Mar S.A.Inventors: Kenneth L. Rinehart, Anna M. Lithgow-Bertelloni
-
Publication number: 20030111020Abstract: Sessile marine organisms are a source of many marine pharmaceuticals. A method of producing such a marine pharmaceutical is provided which involves positioning a plurality of like substrates in sea water, growing the organism on the plurality of substrates, harvesting the grown organism, and extracting the pharmaceutical from the harvested organism.Type: ApplicationFiled: January 31, 2003Publication date: June 19, 2003Applicant: Pharma Mar, S.A.Inventors: Bullent Kukurtcu Targotay, Santiago Naranjo Lozano, Carlos Barbero Garcia, Silvia Martin Benitez
-
Patent number: 6544560Abstract: Sessile marine organisms are a source of many marine pharmaceuticals. A method of producing such a marine pharmaceutical is provided which involves positioning a plurality of like substrates in sea water, growing the organism on the plurality of substrates, harvesting the grown organism, and extracting the pharmaceutical from the harvested organism.Type: GrantFiled: May 29, 2001Date of Patent: April 8, 2003Assignee: Pharma Mar, S.A.Inventors: Kukurtcu Targotay Bullent, Naranjo Lozano Santiago, Barbero Garcia Carlos, Martin Benitez Silvia
-
Publication number: 20020198379Abstract: Palau'amine, of formula I below, may be isolated from a sponge (Stylotella agminata). The compound may be used in the manufacture of pharmaceutical compositions for the treatment of tumors, fungal infections and immunosuppressive affections.Type: ApplicationFiled: June 28, 2002Publication date: December 26, 2002Applicant: Pharma Mar, s.a.Inventors: Robin Bryan Kinnel, Henning-Peter Gehrken, Paul Josef Scheuer, Dolores Garcia Gravalos, Glynn Thomas Faircloth
-
Patent number: RE39887Abstract: Dehydrodidemnin B with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivatives.Type: GrantFiled: June 2, 2005Date of Patent: October 16, 2007Assignee: Pharma Mar, S.A.Inventors: Kenneth L. Rinehart, Anna M. Lithgow-Bertelloni